This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GTCR-Surmodics merger block confirms aggressive antitrust approach under Trump

By Flavia Fortes, Ilana Kowarski and Wesley Brown ( March 7, 2025, 23:29 GMT | Comment) -- With two merger challenges filed in less than two months since taking office, President Donald Trump’s second administration is sending the message that it has no plans to loosen up antitrust enforcement. The Federal Trade Commission sued to block GTCR’s proposed merger with medical device company Surmodics, alleging that the transaction would eliminate head-to-head competition within the market for outsourced hydrophilic coatings. The lawsuit highlights that this administration is also continuing to focus on a sector that has long been a priority for US antitrust law enforcers: healthcare.With two merger challenges filed in less than two months since taking office, President Donald Trump’s second administration is sending the message that it has no plans to loosen up antitrust enforcement....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections